WM - BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards? | Benzinga
BeiGene (NASDAQ: BGNE) is expected to report its fourth-quarter 2023 results soon.
BeiGene currently markets three internally discovered oncology products, including BTK inhibitor, Brukinsa(zanubrutinib), in the United States, China, EU, United Kingdom and additional international markets. The company markets its other products like anti-PD-1 antibody, tislelizumab, in the EU and China, and PARP inhibitor, pamiparib, only in China.
The company has also in-licensed the rights to distribute an additional 14 approved medicines for the China market, which contributes to its top line.
In the past year, shares of BeiGene have plunged 35.3% compared with the industry's 8.7% decline.
Image Source: Zacks Investment Research
Factors to Consider
BeiGene reports its revenues under two segments: Product Revenue and Collaboration Revenue. The company's fourth-quarter revenues are expected to have been driven by the sales of its internally discovered and developed products, as well as increased sales of in-licensed products from Amgen AMGN.
Sales in the Product Revenue segment are likely to have been boosted by the increased sales of Brukinsa and tislelizumab in the fourth quarter of 2023. The U.S. sales of Brukinsa have been skyrocketing as the drug continues to gain market share across all its FDA-approved indications. The positive trend is likely to have continued in the to-be-reported quarter. Brukinsa sales are likely to have increased in China in the to-be-reported quarter as well.
Tislelizumab sales in China are likely to have benefited from rising patient demand and valiant marketing efforts. Sales of additional in-licensed products from Amgen have ...